New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePGPIPN vs Cartalax

PGPIPN vs Cartalax

Side-by-side comparison of key properties, dosing, and research.

Immune Support
PGPIPN
Anti-Aging & Longevity
Cartalax
Summary
PGPIPN is a bioactive hexapeptide (Pro-Gly-Pro-Ile-Pro-Asn) derived from beta-casein during enzymatic digestion. It exhibits anti-inflammatory properties via opioid receptor modulation and cytokine suppression, making it relevant for gut health, systemic inflammation, and as a component of casein-derived functional foods.
Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
Half-Life
Estimated 30-120 minutes (peptide degradation)
Short (minutes); gene-regulatory effects are sustained
Admin Route
Oral, Subcutaneous (research)
SubQ, Oral
Research
Typical Dose
200-500 mg per day
10 mg per day
Frequency
Once or twice daily
Daily for 10–30 days
Key Benefits
  • Anti-inflammatory effects via cytokine suppression
  • Gut mucosal protection and intestinal barrier support
  • Opioid receptor modulation for gut motility regulation
  • Potential analgesic activity via central and peripheral opioid pathways
  • Explored for inflammatory bowel conditions and gut dysbiosis
  • Natural origin (food-derived) with favorable safety profile
  • Supports cartilage matrix synthesis and maintenance
  • May slow progression of osteoarthritic cartilage degradation
  • Reduces chondrocyte apoptosis
  • Promotes joint longevity in aging and high-impact sports
  • Anti-aging effects on connective tissue
  • Complementary to BPC-157 and TB-500 in joint recovery protocols
  • Well tolerated in available human and animal research
Side Effects
  • Generally very well-tolerated given food-derived origin
  • Theoretical opioid-mediated constipation at high doses
  • Rare milk protein allergy in casein-sensitive individuals
  • Generally well tolerated
  • Mild injection site reactions
  • No significant adverse events reported at standard doses
Stacks With